bymuratdenizMoonLake Rises, Competition Wanes: The Sonelokimab Saga Continues MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biotech company developing treatments for autoimmune conditions. Their lead asset, sonelokimab, is an IL-17 inhibitor targeting psoriasis (Phase 3 ready), hidradenitis suppurativa [HS] (Phase 2), and psoriatic arthritis [PsA] (Phase 2). These are all large US markets. Psoriasis is estimated to eclipse $50 billion by 2030. HS is expected to be a $2.24 billion global  ...